BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 36307579)

  • 1. Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors.
    Zhang F; Zhang Q; Zhu J; Yao B; Ma C; Qiao N; He S; Ye Z; Wang Y; Han R; Feng J; Wang Y; Qin Z; Ma Z; Li K; Zhang Y; Tian S; Chen Z; Tan S; Wu Y; Ran P; Wang Y; Ding C; Zhao Y
    Cell Res; 2022 Dec; 32(12):1047-1067. PubMed ID: 36307579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors.
    Gil J; Marques-Pamies M; Valassi E; Serra G; Salinas I; Xifra G; Casano-Sancho P; Carrato C; Biagetti B; Sesmilo G; Marcos-Ruiz J; Rodriguez-Lloveras H; Rueda-Pujol A; Aulinas A; Blanco A; Hostalot C; Simó-Servat A; Muñoz F; Rico M; Ibáñez-Domínguez J; Cordero E; Webb SM; Jordà M; Puig-Domingo M
    Front Endocrinol (Lausanne); 2023; 14():1129213. PubMed ID: 37033229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
    Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of the 2022 WHO Classification of Pituitary Tumors.
    Asa SL; Mete O; Perry A; Osamura RY
    Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annotation of pituitary neuroendocrine tumors with genome-wide expression analysis.
    Tebani A; Jotanovic J; Hekmati N; Sivertsson Å; Gudjonsson O; Edén Engström B; Wikström J; Uhlèn M; Casar-Borota O; Pontén F
    Acta Neuropathol Commun; 2021 Nov; 9(1):181. PubMed ID: 34758873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors.
    Yamato A; Nagano H; Gao Y; Matsuda T; Hashimoto N; Nakayama A; Yamagata K; Yokoyama M; Gong Y; Shi X; Zhahara SN; Kono T; Taki Y; Furuki N; Nishimura M; Horiguchi K; Iwadate Y; Fukuyo M; Rahmutulla B; Kaneda A; Hasegawa Y; Kawashima Y; Ohara O; Ishikawa T; Kawakami E; Nakamura Y; Inoshita N; Yamada S; Fukuhara N; Nishioka H; Tanaka T
    Commun Biol; 2022 Nov; 5(1):1304. PubMed ID: 36435867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell transcriptomics reveal distinct immune-infiltrating phenotypes and macrophage-tumor interaction axes among different lineages of pituitary neuroendocrine tumors.
    Lin S; Dai Y; Han C; Han T; Zhao L; Wu R; Liu J; Zhang B; Huang N; Liu Y; Lai S; Shi J; Wang Y; Lou M; Xie J; Cheng Y; Tang H; Yao H; Fang H; Zhang Y; Wu X; Shen L; Ye Y; Xue L; Wu ZB
    Genome Med; 2024 Apr; 16(1):60. PubMed ID: 38658971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors.
    Yan N; Xie W; Wang D; Fang Q; Guo J; Chen Y; Li X; Gong L; Wang J; Guo W; Zhang X; Zhang Y; Gu J; Li C
    Genome Med; 2024 Jan; 16(1):2. PubMed ID: 38167466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pangenomic Classification of Pituitary Neuroendocrine Tumors.
    Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G
    Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [WHO Histological Classification of Pituitary Tumors].
    Nishioka H
    No Shinkei Geka; 2023 Jul; 51(4):642-653. PubMed ID: 37491061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET.
    Zhang Q; Yao B; Long X; Chen Z; He M; Wu Y; Qiao N; Ma Z; Ye Z; Zhang Y; Yao S; Wang Y; Cheng H; Chen H; Ye H; Wang Y; Li Y; Chen J; Zhang Z; Guo F; Zhao Y
    Cell Rep Med; 2023 Feb; 4(2):100934. PubMed ID: 36754052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
    Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
    Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version].
    Xie J; Wu ZB
    Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative Acetylomics Revealed Acetylation-Mediated Molecular Pathway Network Changes in Human Nonfunctional Pituitary Neuroendocrine Tumors.
    Wen S; Li J; Yang J; Li B; Li N; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():753606. PubMed ID: 34712204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SDF-1α/MicroRNA-134 Axis Regulates Nonfunctioning Pituitary Neuroendocrine Tumor Growth
    Wang X; Fang Y; Zhou Y; Guo X; Xu K; Li C; Zhang J; Hong Y
    Front Endocrinol (Lausanne); 2020; 11():566761. PubMed ID: 33362712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
    Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
    Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic Classification of Pituitary Neuroendocrine Tumors Causing Acromegaly.
    Rymuza J; Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Nyc A; Baluszek S; Zieliński G; Kunicki J; Bujko M
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
    Spada A; Mantovani G; Lania AG; Treppiedi D; Mangili F; Catalano R; Carosi G; Sala E; Peverelli E
    Neuroendocrinology; 2022; 112(1):15-33. PubMed ID: 33524974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole exome sequencing reveals novel risk genes of pituitary neuroendocrine tumors.
    Peculis R; Rovite V; Megnis K; Balcere I; Breiksa A; Nazarovs J; Stukens J; Konrade I; Sokolovska J; Pirags V; Klovins J
    PLoS One; 2022; 17(8):e0265306. PubMed ID: 36026497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylation-Mediated Molecular Pathway Changes in Human Pituitary Neuroendocrine Tumors Identified by Quantitative Phosphoproteomics.
    Li J; Wen S; Li B; Li N; Zhan X
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.